A study to evaluate the effectiveness of Xyzal UC cream in participants with urticaria

Abstract

Objectives: This study aimed to assess the effectiveness and acceptability of Xyzal UC cream, containing the active component Tazman pepper (Tasmanian pepper berry), in alleviating the symptoms of urticaria. Materials and Methods: A prospective, single-center trial was conducted, involving 30 volunteers aged between 18 and 55 years with mild-to-moderate urticaria. Participants were chosen based on specific inclusion and exclusion criteria, which included a recent history of urticaria episodes supported by photographic evidence. The participants were instructed to apply a sufficient quantity of Xyzal UC cream on affected areas during urticaria episodes. Primary endpoints included grading for urticarial symptoms (redness, swelling, and itching) over 90 min and instant cooling and soothing effects of the cream over 15 min post-application using a Likert scale questionnaire. The secondary endpoint was to assess the tolerability of the test product. Photographs of the same site were taken at baseline (before product application), post-application, and after 90 min (or earlier, whenever resolved) by the participants. Results: The average age of participants as per the demographic data was found to be 33.33 years. The study found significant improvements in urticaria symptoms post-application of Xyzal UC cream. At 15 min post-application, 60% of participants agreed that redness had reduced, increasing to 93.3% of the total number of participants at 90 min. Similarly, 66.6% agreed to strongly agreed to a reduction in swelling at 15 min, with this figure rising to 93.3% at 90 min. The itching was notably reduced, with 83.4% of participants agreeing to strongly agreeing for relief from itching at 15 min, and 96.7% at 90 min. Participants also experienced a strong cooling and soothing effect immediately within 1 min post-application with 100% patient agreement. No adverse events or serious adverse events were reported, indicating a good tolerability profile for the cream. Conclusion: Xyzal UC cream exhibited substantial efficacy in promptly alleviating urticaria symptoms, including redness, swelling, and itching, with high levels of participant satisfaction and a positive tolerance profile. The instant cooling and soothing properties of the cream offer immediate relief, positioning it as a promising substitute for conventional therapies often associated with adverse effects. These findings highlight the potential of Xyzal UC cream as a viable and patient-compliant choice for managing mild-to-moderate urticaria.